Mersana Therapeutics News

Truist Financial Sticks to Its Buy Rating for Mersana Therapeutics (MRSN)

TipRanksMay 14 22:05

Analysts Have Conflicting Sentiments on These Healthcare Companies: Mersana Therapeutics (MRSN), Insulet (PODD) and Crispr Therapeutics AG (CRSP)

TipRanksMay 14 17:40

Mersana Therapeutics Inc (MRSN) Reports Q1 2024 Financial Results: A Detailed Analysis

Yahoo FinanceMay 11 03:15

Truist Financial Sticks to Their Buy Rating for Mersana Therapeutics (MRSN)

TipRanksMay 10 20:09

Earnings Call Summary | Mersana Therapeutics(MRSN.US) Q1 2024 Earnings Conference

The following is a summary of the Mersana Therapeutics, Inc. (MRSN) Q1 2024 Earnings Call Transcript:Financial Performance:Mersana reported a healthy balance sheet for Q1 2024, with $183.1 million in

Futu NewsMay 10 06:31 · Conference Call

Mersana Therapeutics, Inc. (MRSN) Q1 2024 Earnings Call Transcript

Mersana Therapeutics, Inc. (MRSN) Q1 2024 Earnings Call Transcript

Earnings Call TranscriptsMay 10 02:09

Mersana Therapeutics | 10-Q: Quarterly report

Futu NewsMay 9 21:02 · Announcements

Mersana Therapeutics Updates Corporate Presentation Online

TipRanksMay 9 19:22

Earnings Flash (MRSN) MERSANA THERAPEUTICS Posts Q1 Revenue $9.2M, Vs. Street Est of $8.5M

07:03 AM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (MRSN) MERSANA THERAPEUTICS Posts Q1 Revenue $9.2M, vs. Street Est of $8.5M

MT NewswiresMay 9 19:03

Mersana Therapeutics 1Q Loss/Shr 16c >MRSN

Mersana Therapeutics 1Q Loss/Shr 16c >MRSN

Dow JonesMay 9 18:59

Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024

CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates

GlobeNewswireMay 2 20:00

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Not Doing Enough For Some Investors As Its Shares Slump 34%

Mersana Therapeutics, Inc. (NASDAQ:MRSN) shares have had a horrible month, losing 34% after a relatively good period beforehand.

Simply Wall StApr 26 18:32

Why Teledyne Technologies Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Shares of Teledyne Technologies Incorporated (NYSE:TDY) fell sharply during Wednesday's session after the company reported worse-than-expected first-quarter financial results and cut FY24 adjusted EPS

BenzingaApr 25 01:57

Mersana Therapeutics (NASDAQ:MRSN Investor Three-year Losses Grow to 80% as the Stock Sheds US$68m This Past Week

While not a mind-blowing move, it is good to see that the Mersana Therapeutics, Inc. (NASDAQ:MRSN) share price has gained 20% in the last three months. But the last three years have seen a terrible

Simply Wall StApr 20 20:06

Daily rights tracking | Trump's media rose 40% in two days! Earn eight times the option premium with a single call

Tesla's multiple single options due today doubled and surged; TSMC options trading volume surged by nearly 60%, slightly rising to 68% from a bullish ratio.

Futu NewsApr 19 17:03

Daily ticket tracking | Big users are feverishly hoarding call lists! Meta's bullish ratio is already over 70%

Intel plummeted more than 5% last Friday, and options transactions rose to 430,000. The 33-dollar deposit due this Friday earned six times the premium; J.P. Morgan's stock price fell more than 6% after the results, and options trading volume surged to nearly 3 times the average daily turnover.

Futu NewsApr 15 17:03

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates

GlobeNewswireApr 5 04:30

Daily rights tracking | Tesla's $170 equity position was snatched and delivered or challenged in the first quarter; Micron Options trading volume surged! Multiple call single transactions are hot

AMC cinemas fell nearly 28% over the two days, with options trading volume of 240,000, up more than 130% from the average daily turnover, and the bearish ratio rose to 44%. Single option premiums due on Friday with an exercise price of $3 surged fivefold, with a trading volume of 24,000 shares and nearly 5,000 unclosed positions.

Futu NewsApr 2 17:07

JP Morgan Upgrades Mersana Therapeutics to Neutral, Announces $5 Price Target

JP Morgan analyst Brian Cheng upgrades Mersana Therapeutics from Underweight to Neutral and announces $5 price target.

Analyst UpgradesMar 19 17:50

12 Health Care Stocks Moving In Friday's After-Market Session

GainersCue Health (NASDAQ:HLTH) shares increased by 12.1% to $0.22 during Friday's after-market session. The company's market cap stands at $34.8 million. As per the press release, Q4 earnings came ou

BenzingaMar 16 05:33